First Trust Advisors LP Boosts Stock Position in Boston Scientific Corporation $BSX

Key Points

• First Trust Advisors boosted its stake in Boston Scientific by 11.5%, buying 49,545 shares to hold 479,182 shares worth about $46.8 million, and institutional investors now own roughly 89.07% of the company.
• Boston Scientific slightly beat quarterly EPS expectations (EPS $0.80 vs. $0.78) with revenue up 15.9% year‑over‑year and set Q1 2026 guidance of $0.780–0.800 and FY 2026 guidance of $3.430–3.490, while analysts maintain a consensus "Moderate Buy" with a $108 price target.
• Multiple class actions and investigations have been filed covering purchases from July 23, 2025 to Feb 3, 2026, creating a legal overhang, and CEO Michael F. Mahoney sold 160,901 shares (a ~10.23% reduction in his holdings), which may pressure near‑term sentiment.

First Trust Advisors LP lifted its holdings in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 11.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 479,182 shares of the medical equipment provider's stock after buying an additional 49,545 shares during the quarter. First Trust Advisors LP's holdings in Boston Scientific were worth $46,782,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in BSX. Vanguard Group Inc. grew its position in shares of Boston Scientific by 0.8% in the third quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider's stock valued at $13,497,294,000 after purchasing an additional 1,115,337 shares during the period. State Street Corp lifted its stake in Boston Scientific by 1.1% in the 2nd quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider's stock valued at $7,002,258,000 after buying an additional 713,379 shares in the last quarter. Geode Capital Management LLC lifted its stake in Boston Scientific by 2.0% in the 2nd quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider's stock valued at $3,466,320,000 after buying an additional 622,602 shares in the last quarter. Norges Bank acquired a new stake in Boston Scientific in the 2nd quarter worth about $2,089,937,000. Finally, Invesco Ltd. increased its stake in Boston Scientific by 1.4% during the 2nd quarter. Invesco Ltd. now owns 16,851,518 shares of the medical equipment provider's stock worth $1,810,022,000 after buying an additional 226,578 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Boston Scientific Price Performance

BSX stock opened at $69.58 on Thursday. Boston Scientific Corporation has a 1 year low of $68.19 and a 1 year high of $109.50. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. The firm has a market capitalization of $103.24 billion, a PE ratio of 35.86, a price-to-earnings-growth ratio of 0.98 and a beta of 0.69. The business has a 50 day simple moving average of $83.51 and a 200-day simple moving average of $93.81.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts' consensus estimates of $0.78 by $0.02. The company had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The firm's revenue for the quarter was up 15.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Equities research analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on BSX shares. TD Cowen decreased their target price on Boston Scientific from $115.00 to $100.00 and set a "buy" rating on the stock in a research report on Monday, February 2nd. Truist Financial dropped their price target on Boston Scientific from $120.00 to $95.00 and set a "buy" rating for the company in a research report on Thursday, February 5th. Weiss Ratings downgraded Boston Scientific from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Wednesday, February 4th. Wall Street Zen lowered Boston Scientific from a "buy" rating to a "hold" rating in a report on Saturday, February 7th. Finally, Argus raised shares of Boston Scientific to a "strong-buy" rating in a research note on Thursday, February 26th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $108.00.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Citigroup cut its price target on BSX from $102 to $94 but kept a "buy" rating — signaling the firm still sees meaningful upside even after lowering near-term expectations. This preserves analyst support that can limit downside pressure. Citigroup Lowers PT
• Neutral Sentiment: Unusually large volume of put-option purchases was reported, indicating traders are hedging or speculating on further downside; this raises short‑term volatility but can reflect transient positioning rather than a change in fundamentals. Put Options Flow
• Negative Sentiment: Multiple law firms have filed or announced investigations and class actions against Boston Scientific covering purchases between July 23, 2025 and Feb 3, 2026; plaintiffs allege securities-law violations. A growing wave of litigation increases legal risk, potential discovery costs, and an overhang that often weighs on shares. Bronstein Class Action
• Negative Sentiment: Numerous plaintiff firms (including Rosen, Faruqi, RGRD, Bragar Eagel & Squire, and others) are soliciting lead-plaintiff motions and reminding shareholders of the May 4, 2026 deadline — amplifying publicity and the probability of consolidated litigation. That sustained media/legal attention typically pressures near-term sentiment and can increase legal-cost uncertainty. Deadline Reminder

Insider Buying and Selling at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of the company's stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer owned 1,411,735 shares of the company's stock, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 0.50% of the company's stock.

Boston Scientific Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.